Table 4. Subgroup analysis: meta-analysis results according to the type of cancer.
Subgroup | OR | (95%CI) | PZ | PH | I2 (%) | Effects model |
---|---|---|---|---|---|---|
Breast cancer | ||||||
Dominant model (GG vs GA+AA) | 2.75 | (1.54–4.90) | 0.0006 | 0.73 | 0% | Fixed |
Recessive model (GG+GA vs AA) | 0.59 | (0.37–0.95) | 0.03 | 0.38 | 0% | Fixed |
Co-dominant model (GG vs GA) | 0.41 | (0.23–0.74) | 0.003 | 0.60 | 0% | Fixed |
Co-dominant model (GG vs AA) | 0.28 | (0.14–0.56) | 0.0003 | 0.81 | 0% | Fixed |
Allele model (A vs G) | 0.61 | (0.46–0.82) | 0.001 | 0.68 | 0% | Fixed |
Allele model (G vs A) | 1.63 | (1.22–2.19) | 0.001 | 0.68 | 0% | Fixed |
Colorectal cancer | ||||||
Dominant model (GG vs GA+AA) | 0.53 | (0.35–0.80) | 0.002 | 0.78 | 0% | Fixed |
Recessive model (GG+GA vs AA) | 1.81 | (0.66–4.99) | 0.25 | 0.13 | 56% | Random |
Co-dominant model (GG vs GA) | 1.74 | (1.14–2.67) | 0.01 | 0.58 | 0% | Fixed |
Co-dominant model (GG vs AA) | 2.46 | (1.34–4.51) | 0.004 | 0.32 | 0% | Fixed |
Esophageal cancer | ||||||
Dominant model (GG vs GA+AA) | 0.44 | (0.15–1.26) | 0.13 | 0.010 | 85% | Random |
Recessive model (GG+GA vs AA) | 1.51 | (1.05–2.16) | 0.03 | 0.98 | 0% | Fixed |
Co-dominant model (GG vs GA) | 2.11 | (0.65–6.88) | 0.22 | 0.005 | 87% | Random |
Co-dominant model (GG vs AA) | 2.51 | (1.10–5.71) | 0.03 | 0.09 | 64% | Random |
Cervical cancer | ||||||
Dominant model (GG vs GA+AA) | 0.92 | (0.64–1.32) | 0.64 | 0.34 | 0% | Fixed |
Recessive model (GG+GA vs AA) | 1.52 | (0.60–3.90) | 0.38 | 0.005 | 87% | Random |
Co-dominant model (GG vs GA) | 0.93 | (0.63–1.37) | 0.71 | 0.88 | 0% | Fixed |
Co-dominant model (GG vs AA) | 1.45 | (0.55–3.85) | 0.46 | 0.02 | 81% | Random |
Abbreviations: PZ, P-value for Z-test; PH, P-value for heterogeneity. Statistically significant values shown in bold.